Invention Grant
- Patent Title: Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
-
Application No.: US16744140Application Date: 2020-01-15
-
Publication No.: US11357832B2Publication Date: 2022-06-14
- Inventor: Ann Barbier , Thomas Mccauley , Charles W. Richard, III
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Proskauer Rose LLP
- Agent Fangli Chen
- Main IPC: C12N9/16
- IPC: C12N9/16 ; A61K38/46 ; A61K9/00

Abstract:
The present invention, provides a method of treating cognitive impairment of Hunter syndrome. Among other things, the present invention provides a method comprising a step of administering intrathecally to a subject in need of treatment a recombinant iduronate-2-sulfatase (I2S) enzyme at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce declining of one or more cognitive, adaptive, motor, and/or executive functions relative to a control.
Public/Granted literature
- US20200376093A1 TREATMENT OF COGNITIVE IMPAIRMENT OF HUNTER SYNDROME BY INTRATHECAL DELIVERY OF IDURONATE-2-SULFATASE Public/Granted day:2020-12-03
Information query